Communiqués Nykode Therapeutics OTC Markets

Actions

VACBF

NO0010714785

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 21:31:02 06/10/2023			Varia. 5j.	Varia. 1 janv.
2,250 ^USD	-1,75%		+535,23%	+1 344,62%

20/08	Nykode Therapeutics obtient un nouveau brevet aux États-Unis pour son vaccin contre le cancer à base de néoantigènes	MT
06/08	Nykode Therapeutics ASA annonce la nomination de Jakob Helding Rasmussen au poste de Chief Technology Officer	CI

Communiqués

20/08	Nykode Therapeutics : Receives New U.S. Patent Strengthening Intellectual Property Protection for its fully individualized VB10.NEO cancer vaccine program	PU
06/08	Nykode Therapeutics : Grant of share options	PU
22/07	Nykode Therapeutics Presents Comprehensive Preclinical Data, Optimized Manufacturing, and Durable Clinical Immunogenicity for their Individualized Neoantigen Therapy VB10.NEO	AQ
27/05	Nykode Therapeutics : Q1 2026 Financial Results Q1 2026 Webcast presentation	PU
27/05	Nykode Therapeutics : Q1 2026 Financial Results Nykode Q1 2026 Report	PU
27/05	Nykode Therapeutics : reports Q1 2026 Financial Results	PU
27/05	Nykode Therapeutics - Quarterly Report Q1 2026	AQ
18/05	Nykode Therapeutics : Invitation to Q1 2026 Financial Results Presentation	PU
18/05	Nykode Therapeutics - Invitation to Q1 2026 Financial Results Presentation	AQ
13/05	Nykode Therapeutics ASA - Minutes of Annual General Meeting	AQ
07/05	Nykode Therapeutics Doses First Patient in Abili-T Phase II Randomized Trial evaluating Abi-suva in HPV16-Positive, PD-L1-Positive Recurrent or Metastatic Head and Neck Cancer Patients	AQ
30/04	Nykode Therapeutics Presents AI-Powered Immunotherapy Design Capabilities at BioPharma Drug Discovery Nexus 2026	AQ
20/04	Nykode Therapeutics Presents Additional Immunogenicity Data from VB-C-03 Trial at the 2026 American Association for Cancer Research (AACR) Annual Meeting	AQ
17/04	Nykode Therapeutics : Annual Report 2025 Nykode Annual Report 25	PU
17/04	Nykode Therapeutics : Annual Report 2025	PU
17/04	Nykode Therapeutics : Annual Report 2025	PU
21/03	Nykode Therapeutics Highlights Robust Immunogenicity and Promising Clinical Activity for Abi-Suva at ICHNO 2026	AQ
18/03	Nykode Therapeutics : Announces Upcoming Presentations at AACR 2026 and NextGen Biomed 2026	PU
18/03	Nykode Therapeutics : Announces Upcoming Presentations at AACR 2026 and NextGen Biomed 2026	PU
09/03	Nykode Therapeutics to Present at DNB Carnegie Conference on March 10, 2026	AQ
03/03	Nykode Therapeutics to Present New Data and Participate in Panel Discussion at the 9th Annual Antigen-Specific Immune Tolerance Summit (ASIT)	AQ
27/02	Nykode Therapeutics : Q4 2025 Financial Results Q4 2025 Webcast presentation	PU
25/02	Nykode Therapeutics : ABG Investor Presentation	PU
25/02	Nykode Therapeutics : reports Q4 2025 Financial Results	PU
25/02	Nykode Therapeutics : Q4 2025 Financial Results Nykode Q4 2025 Report	PU